Medical Xpress August 26, 2024
A new study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system, estimates that 3.6 million Medicare beneficiaries are most likely to become eligible for semaglutide.
If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible, while new federal spending could still exceed $10 billion.
Current federal regulation restricts Medicare from covering drugs prescribed solely for weight loss. However, in March 2024, Medicare announced it would extend coverage to semaglutide (Wegovy), a popular glucagon-like peptide-1 receptor agonist (GLP-1RA), for patients with elevated body mass index (BMI) who also had established cardiovascular disease (CVD).
This means that the definition of “established CVD,” which has not been...
Today's Sponsors
Today's Sponsor